DB
CRSP icon

Dmitry Balyasny’s CRISPR Therapeutics CRSP Stock Holding History

Dmitry Balyasny’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,202
Closed -$1.11M – 2981
2025
Q4 		$1.11M Buy
+21,202
New +$1.27M ﹤0.01% 2141
2025
Q2 		– Sell
-83,467
Closed -$2.84M – 2902
2025
Q1 		$2.84M Sell
83,467
-810,468
-91% -$34.4M ﹤0.01% 1527
2024
Q4 		$35.2M Buy
893,935
+270,285
+43% +$12.8M 0.05% 441
2024
Q3 		$29.3M Buy
623,650
+532,986
+588% +$27M 0.05% 493
2024
Q2 		$4.9M Buy
+90,664
New +$5.24M 0.01% 1179
2023
Q1 		– Sell
-64,580
Closed -$2.63M – 2730
2022
Q4 		$2.63M Buy
64,580
+42,018
+186% +$2.23M 0.01% 1289
2022
Q3 		$1.48M Buy
+22,562
New +$1.64M ﹤0.01% 1648
2022
Q2 		– Sell
-7,016
Closed -$440K – 2818
2022
Q1 		$440K Buy
7,016
+1,169
+20% +$73.4K ﹤0.01% 1842
2021
Q4 		$443K Sell
5,847
-4,841
-45% -$423K ﹤0.01% 1647
2021
Q3 		$1.2M Buy
+10,688
New +$1.34M 0.01% 1283
2021
Q1 		– Sell
-3,418
Closed -$523K – 1802
2020
Q4 		$523K Sell
3,418
-96,384
-97% -$11.4M ﹤0.01% 1123
2020
Q3 		$8.35M Buy
99,802
+93,839
+1,574% +$8.32M 0.06% 447
2020
Q2 		$438K Buy
+5,963
New +$349K ﹤0.01% 941
2019
Q3 		– Sell
-109,657
Closed -$5.17M – 1237
2019
Q2 		$5.17M Buy
+109,657
New +$4.38M 0.03% 596

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dmitry Balyasny's CRSP Position: Q1 2026 in Review

Dmitry Balyasny sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 21,202 shares — an estimated $1.11M sold.

Dmitry Balyasny first reported a position in CRSP in Q2 2019 and held it in 14 quarters. The position peaked at $35.2M in Q4 2024. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Dmitry Balyasny reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 21,202 CRISPR Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Dmitry Balyasny first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 14 quarters.
  • Dmitry Balyasny's CRISPR Therapeutics position peaked at $35.2M in Q4 2024.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.